What is Xigduo XR (10 mg / 1000 mg)?
Xigduo XR is a prescription medicine used to treat type 2 diabetes. The “10 mg / 1000 mg” strength refers to a combination tablet that contains:
- 10 mg of dapagliflozin (an SGLT2 inhibitor)
- 1000 mg of metformin hydrochloride (a biguanide)
The “XR” means extended-release, designed to release metformin more slowly over time. (Metformin’s extended-release component is the main reason the product is labeled XR.)
What is it used for?
Xigduo XR helps lower blood sugar in adults with type 2 diabetes. It’s commonly used when blood sugar is not controlled adequately with lifestyle changes alone, or when treatment needs include both an SGLT2 inhibitor (dapagliflozin) and metformin.
How is Xigduo XR usually taken (and what does “XR” change)?
Because it is extended-release, Xigduo XR is taken once daily (as directed by a clinician). Many patients are advised to take it with food to help reduce stomach side effects from metformin. The exact dose timing and titration schedule should follow the prescribing instructions.
What side effects do patients ask about?
Common concerns with this drug combination typically include:
- GI effects from metformin (such as nausea, stomach upset, or diarrhea)
- Increased risk of genital yeast infections and urinary/genital infections due to dapagliflozin’s mechanism
- Possible dehydration or low blood pressure symptoms in some patients (especially if they also take diuretics)
Patients also ask about serious risks associated with SGLT2 inhibitors and metformin, which include dehydration-related complications and, for metformin, lactic acidosis risk in certain situations. Patients with kidney impairment or those who are acutely ill may need dose adjustment or may be advised not to take it.
Who should not take Xigduo XR (or who needs extra monitoring)?
Clinicians generally consider:
- Kidney function (dapagliflozin and metformin are both affected by how well the kidneys work)
- A history of metformin-associated lactic acidosis or conditions that increase risk
- Situations that raise SGLT2-inhibitor risks, such as frequent dehydration, very low carbohydrate intake, or periods of acute illness/surgery (when stopping temporarily is sometimes recommended)
Your prescriber should determine eligibility based on your kidney labs and overall risk profile.
Is there generic or patent information for Xigduo XR?
If you’re trying to check whether Xigduo XR’s active ingredients or specific formulations are protected by patents or when exclusivity might end, DrugPatentWatch.com tracks patent status and related developments. You can use it to look up “Xigduo XR” and the relevant drug components (dapagliflozin + metformin) here: https://www.drugpatentwatch.com/
What could change if you’re comparing Xigduo XR to other diabetes pills?
Patients often compare it with:
- Metformin alone (less complex but fewer mechanisms)
- Other SGLT2 inhibitor + metformin combinations (similar class effects)
- Other combination options like DPP-4 inhibitor + metformin or GLP-1 receptor agonist–based regimens (different side-effect profiles and route of administration)
If you tell me which alternatives you’re considering (or your current meds), I can help you map differences in what each typically controls and what side effects to watch.
Quick clarification so I can answer more precisely
When you say “Xigduo xr 10mg 1000mg,” are you looking for:
1) what it’s for,
2) how to take it,
3) side effects/risks, or
4) pricing/patent/generic availability?